NCT06478472
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Bing, Xu Xiamen, Fujian, China
Clinical trial condition
Lymphoma, B-Cell, Marginal Zone
Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.
647 public trials
86 recruiting studies
Lymphoma, B-Cell, Marginal Zone trial results
NCT06513234
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, China
NCT06454968
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Peking Union Medical College Hospital Beijing, Beijing Municipality, China
NCT06134284
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- The Second Affiliated Hospital of Zhejiang University, Ningbo First Hospital Hangzhou, Zhejiang, China
- 86-574-87085596 Ningbo, Zhejiang, China
- The First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China
Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
NCT05846750
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Institute of Hematology & Blood Diseases Hospital Tianjin, Tian, China
NCT03869619
- Conditions
- Burkitt Lymphoma, Burkitt Lymphoma (BL)), DNA Virus Infections, +26 more
- Locations
-
- Unité d'Hématologie Clinique, CH D'ARRAS Arras, France
- Service d'Hématologie, CHU Jean Minjoz Besançon, France
- Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine Bordeaux, France
- Institut Bergonié Bordeaux, France
Not yet recruiting
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
NCT07713459
- Conditions
- CAR T Cell Therapy, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell Non-Hodgkin's Lymphoma, +14 more
- Locations
-
Not specified
Not yet recruiting
Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
NCT07711327
- Conditions
- Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Fibrillation (AF), +35 more
- Locations
-
- City of Hope Duarte, California, United States
- UC San Diego Health San Diego, California, United States
- Stanford Health Care Stanford, California, United States
Not yet recruiting
A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
NCT07705308
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
- Fudan University Affiliated Minhang Hospital Shanghai, Shanghai Municipality, China
- Huadong Hospital Shanghai, Shanghai Municipality, China
Not yet recruiting
Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
NCT07638722
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
- Locations
-
Not specified